(Q38016342)

27 August 2017

title

Carbohydrate-based cancer vaccines: target cancer with sugar bullets (English)

1 reference

27 August 2017

Chang-Cheng Liu

1

0 references

author name string

Xin-Shan Ye

series ordinal

2

1 reference

27 August 2017

publication date

6 June 2012

1 reference

27 August 2017

published in

Glycoconjugate Journal

1 reference

27 August 2017

volume

29

1 reference

27 August 2017

issue

5-6

1 reference

27 August 2017

page(s)

259-271

1 reference

https://scigraph.springernature.com/pub.10.1007/s10719-012-9399-9

27 August 2017

exact match

0 references

cites work

Immune therapy for cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Translating tumor antigens into cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

GM-CSF-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Dendritic cell vaccines in melanoma: from promise to proof?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Lectin-like oxidized low-density lipoprotein receptor-1 delivers heat shock protein 60-fused antigen into the MHC class I presentation pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Tumor antigens as surrogate markers and targets for therapy and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Immunotherapy of autoimmunity and cancer: the penalty for success

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Carbohydrate antigens as targets for active specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Lewis blood group and CEA related antigens; coexpressed cell-cell adhesion molecules with roles in the biological progression and dissemination of tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Glycoprotein glycosylation and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Tumour-associated carbohydrate antigens in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Cancer vaccines and carbohydrate epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Metastases: the glycan connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Carbohydrate vaccines: developing sweet solutions to sticky situations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Automated solid-phase synthesis of oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Designing the optimal vaccine: the importance of cytokines and dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Chemokines and cell migration in secondary lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Monoclonal antibodies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Complement and its role in innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside‐KLH Conjugate Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Therapeutic vaccines in solid tumours: can they be harmful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Vaccination with Theratope (STn-KLH) as treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Carbohydrate vaccines as immunotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Mucins in cancer: protection and control of the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Pursuit of optimal carbohydrate-based anticancer vaccines: preparation of a multiantigenic unimolecular glycopeptide containing the Tn, MBr1, and Lewis(y) antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Carrier-priming leads to hapten-specific suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Immunotherapy for cancer: synthetic carbohydrate-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Identification and functions of pattern-recognition receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Immature, but not inactive: the tolerogenic function of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Mannose receptor-targeted vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Lipopeptides containing 2-(palmitoylamino)-6,7-bis(palmitoyloxy) heptanoic acid: synthesis, stereospecific stimulation of B-lymphocytes and macrophages, and adjuvanticity in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Modulation of innate immune responses with synthetic lipid A derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Synthesis and biological evaluation of a multiantigenic Tn/TF-containing glycopeptide mimic of the tumor-related MUC1 glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Robust immune responses elicited by a fully synthetic three-component vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Synthesis of a single-molecule L-rhamnose-containing three-component vaccine and evaluation of antigenicity in the presence of anti-L-rhamnose antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Structural features of polysaccharides that induce intra-abdominal abscesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

The love-hate relationship between bacterial polysaccharides and the host immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Polysaccharide processing and presentation by the MHCII pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Microbial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

The entirely carbohydrate immunogen Tn-PS A1 induces a cancer cell selective immune response and cytokine IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Nanoparticle delivery systems in cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Metabolic oligosaccharide engineering as a tool for glycobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Modulating cell surface immunoreactivity by metabolic induction of unnatural carbohydrate antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Recent development in carbohydrate-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Efficient metabolic engineering of GM3 on tumor cells by N-phenylacetyl-D-mannosamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Synthetic and immunological studies of 5'-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Synthetic and Immunological Studies of sTn Derivatives Carrying 5-N-(p-Substituted Phenylacetyl)Sialic Acid for the Development of Effective Cancer Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Synthesis and immunochemical characterization of S-linked glycoconjugate vaccines against Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

S-linked ganglioside analogues for use in conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Chemical and chemoenzymatic synthesis of S-linked ganglioside analogues and their protein conjugates for use as immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Cell-mediated immune responses to MUC1 fusion protein coupled to mannan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Towards a Fully Synthetic Carbohydrate-Based Anticancer Vaccine: Synthesis and Immunological Evaluation of a Lipidated Glycopeptide Containing the Tumor-Associated Tn Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Synthesis of Glyco(lipo)peptides by Liposome-Mediated Native Chemical Ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

Preparation of multifunctional glyconanoparticles as a platform for potential carbohydrate-based anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10719-012-9399-9

GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines

21 January 2018

1 reference

12 December 2020

Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen.

1 reference

12 December 2020

Tumor-Associated Carbohydrate Antigens Defining Tumor Malignancy: Basis for Development of Anti-Cancer Vaccines

1 reference

12 December 2020

Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine.

1 reference

12 December 2020

Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PS A1 conjugates

1 reference

12 December 2020

A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response

1 reference

12 December 2020

Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen

1 reference

12 December 2020

Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines

1 reference

12 December 2020

Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway

1 reference

12 December 2020

Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer

1 reference

12 December 2020

Complement regulators and inhibitory proteins

1 reference

12 December 2020

A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy

1 reference

12 December 2020

Antigenic targeting of the human mannose receptor induces tumor immunity

1 reference

12 December 2020

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer

1 reference

12 December 2020

N-linked oligosaccharide processing and tumor cell biology

1 reference

12 December 2020

Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients

1 reference

12 December 2020

Iterative one-pot synthesis of oligosaccharides

1 reference

12 December 2020

Synthetic Antitumor Vaccines Containing MUC1 Glycopeptides with Two Immunodominant Domains-Induction of a Strong Immune Response against Breast Tumor Tissues

1 reference

12 December 2020

Enzymatic basis for the structural changes of asparagine-linked sugar chains of membrane glycoproteins of baby hamster kidney cells induced by polyoma transformation.

1 reference

12 December 2020

Synthesis of fluorinated Thomsen–Friedenreich antigens: direct deoxyfluorination of αGalNAc-threonine tert-butyl esters

1 reference

12 December 2020

Preparation of a multiple antigen glycopeptide (MAG) carrying the Tn antigen. A possible approach to a synthetic carbohydrate vaccine.

1 reference

12 December 2020

B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity.

1 reference

12 December 2020

Biochemical engineering of surface alpha 2-8 polysialic acid for immunotargeting tumor cells

1 reference

12 December 2020

Fluorinated Glycosyl Amino Acids for Mucin-Like Glycopeptide Antigen Analogues

1 reference

12 December 2020

The unfulfilled promise of melanoma vaccines

1 reference

12 December 2020

Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate.

1 reference

12 December 2020

Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids

1 reference

12 December 2020

GM-CSF-secreting vaccines for solid tumors.

1 reference

12 December 2020

Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia

1 reference

12 December 2020

Sialosyl-Tn antigen as a marker of gastric cancer progression: an international study

1 reference

12 December 2020

Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway

1 reference

12 December 2020

Oncogenes conferring metastatic potential induce increased branching of Asn-linked oligosaccharides in rat2 fibroblasts.

1 reference

12 December 2020

GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21

1 reference

12 December 2020

Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21

1 reference

12 December 2020

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

1 reference

12 December 2020

Synthesis of a MUC1-glycopeptide–BSA conjugate vaccine bearing the 3′-deoxy-3′-fluoro-Thomsen–Friedenreich antigen

1 reference

12 December 2020

Kinetics of costimulatory molecule expression by T cells and dendritic cells during the induction of tolerance versus immunity in vivo

1 reference

12 December 2020

Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines

1 reference

12 December 2020

Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines

1 reference

12 December 2020

A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response

1 reference

12 December 2020

Thiooligosaccharide conjugate vaccines evoke antibodies specific for native antigens

1 reference

12 December 2020

10.1007/S10719-012-9399-9

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1030004760

0 references

1 reference